Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360810 | 1.00 | DGAT1 (0.37) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL15310123 | 0.87 | DGAT1 (0.38) | DGAT1PTGDR2PYCR1APLNRAAK1 | |
| SCHEMBL23062594 | 0.86 | DGAT1 (0.37) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL362523 | 0.84 | DGAT1 (0.40) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL362524 | 0.84 | DGAT1 (0.40) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL1173372 | 0.82 | DGAT1 (0.37) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL247850 | 0.82 | DGAT1 (0.37) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL1173257 | 0.82 | DGAT1 (0.37) | DGAT1PTGDR2PTPN7DUSP3USP28 | |
| SCHEMBL360540 | 0.81 | DGAT1 (0.41) | DGAT1PTGDR2PTPN7DUSP3PYCR1 | |
| SCHEMBL30374570 | 0.81 | DGAT1 (0.41) | DGAT1PTGDR2PTPN7DUSP3PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3504211-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | Eli Lilly and Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2018039062-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| US-8846658-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CN) | 2014-04-24 | — | — | US | disclosed |
| WO-2012095451-A1 | CRYSTALLINE OXAZINE DERIVATIVE AND ITS USE AS BACE INHIBITOR | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | NOVARTIS PHARMA AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | DGAT1 718/4885PTGDR2 3479/4885PTPN7 2861/4885 |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | DGAT1 3947/4885PTGDR2 262/4885PTPN7 2721/4885 |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | BACE1, BACE2, PSEN1 | DGAT1 2151/4885PTGDR2 4745/4885PTPN7 2834/4885 |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | CYP3A5, CHRM5, CYP2C8 | DGAT1 4278/4885PTGDR2 2036/4885PTPN7 2574/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | DGAT1 3947/4885PTGDR2 262/4885PTPN7 2721/4885 |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | DGAT1 3947/4885PTGDR2 262/4885PTPN7 2721/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | DGAT1 3947/4885PTGDR2 262/4885PTPN7 2721/4885 |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | DGAT1 2151/4885PTGDR2 4745/4885PTPN7 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.